Schistosoma mansoni 28 kDa glutathione S-transferase (Sm28GST) (Sm28GST)

The Schistosoma mansoni 28 kDa glutathione S-transferase (Sm28GST), also known as P28GST, is a critical enzyme and a prominent vaccine candidate for schistosomiasis (UniProt P09212). It functions as a detoxification enzyme by catalyzing the conjugation of reduced glutathione to electrophilic substrates, protecting the parasite from oxidative stress and host immune attacks (PubMed: 15848277). The glutathione cofactor site (G-site) is the specific structural pocket where glutathione binds to enable this catalytic activity (PDB: 1M92). Beyond its antioxidant role, Sm28GST is involved in the synthesis of prostaglandins, which helps the parasite modulate host inflammatory responses and facilitate tissue penetration (PubMed: 11544350). Therapeutic interventions, such as the Bilharvax vaccine, aim to induce antibodies that neutralize the enzyme's activity, leading to a significant reduction in parasite fecundity and egg-induced pathology (PubMed: 22414340). Small molecule inhibitors targeting the G-site are also being explored to compromise the parasite's essential defense mechanisms.

Other names

P28GSTSm2828 kDa glutathione S-transferaseGlutathione S-transferase P28Glutathione cofactor site on P28GSTGlutathione-binding site of Sm28GST

The target is addressed primarily through the induction of neutralizing antibodies via vaccination, which bind to the enzyme and inhibit its catalytic function, thereby reducing parasite survival and egg production (PubMed: 22414340). Additionally, small molecule inhibitors can target the glutathione cofactor site (G-site) to competitively inhibit the enzyme, disrupting the parasite's ability to neutralize host-derived reactive oxygen species and xenobiotics (PubMed: 15848277).